Monkshood, many thanks for your information. I was asking a lab technician in our local hospital about BAMS and that was the information I was given.
It sounds to me that your level of expertise on this is far greater than I was able to glean from a short three to four-minute conversation!
The information shared, is very helpful. Thank you very much for sharing. As well as the other links below. It gives us all a much greater understanding.
From this weeks information from Avacta, this is surely one of the most interesting and informative presentations yet?
I think he most likely is invested from that time! This investment was discussed in many BMN groups and he may be in one of those.
My first buy was at 38p also. £50k.
Great investment and now hold a very strong investment here.
Zoom, I am not surprised at all to see so many Bushveld Minerals investors building a holding here. There are some very high net worth individuals who I know well on that board and building a holding here quietly is highly likely. They all like companies with great fundamentals and huge upside.
Avacta is a perfect Investment for these investors. Well managed, excellent communication and very clear long term upside. The key to a good investment is to have the right ingredients. Bushveld went from 5p to 50p. It currently sits at the bottom of a cycle but it remains one of the highest earning AIM listed miners and mineral processors. With significant profit.
I only point this out, because if Avacta complete the trio with Covid19 and progress with the pre|CISION cancer treatments they will have profits and growth like no other AIM investment. Exceeding Boohoo and other high value AIM companies market caps.
The other common point is duel listing and move to the FTSE is likely with both businesses in the future.
I feel currently that Avacta has the ability to our pace BMN over the next 12 months, but both will be very successful companies.
Anyway here and now my focus and all here are interested in Avacta.
Nice to see people building there holdings here.
This came up in an earlier post - what else could Avacta do with LFD using Affimers?
If they can match the proteins for diseases, cancers, viruses, then surely there is no limit to its uses. Imagine instead of a CT scan you could use an LFD for looking for the specific cancer cell and mean the correct pre|CISION product with the attached drug could be focused to destroy that tumour. This could take away weeks of waiting and take us to the right specialist and save health services around the world billions. This diagnostic market has massive potential! This is just the second use that Avacta has got to the point where it is close to market readiness!
I want to make some comments for the record in line with the subject.
I have always taken the approach with this share chat on LSE is to of course to share thoughts and discussion and this is very good to give balance. I also believe that many people actually jump from board to board looking for why a company is a potential investment and people look for summaries of information which can help them research. That is why I do keep the lists and introductions up to date and share regularly.
The one thing you can be sure which will put private investors off is a board full of pointless comments and aggression towards people. I have always been fair and in my posting history I have only on a few occasions picked people up for suspicious activity. When I do I have been proved correct.
I think it is important for board etiquette to be fair and respectful to each other. I have made that point many times.
In this area of amateur private investors, there are many vulnerable posters who are looking for help and assurance. But this market and AIM is full of companies which are ambitious but are unlikely to succeed. So when good ones come along especially with exceptional 'IP' like Avacta with a positive future and one which will help mankind as a whole, I am very happy to share as many facts as possible and point where more research can be found. I am not always correct and I think we can safely say nobody is! But in this case, Avacta has exceptionally good prospects to become either a FTSE company or be bought by a large global pharmaceutical giant for a value which is going to be very acceptable to investors who are invested.
The Covid19 testing and therapeutics will be the key turning point for Avacta and its opportunity to use its Affimer technology in the important diagnostics market is in itself highly valuable, but the real value and the technology which will take it from a very strong Biotech company to a mega one is the pre|CISION Therapeutics focusing on targeted Chemotherapy which has the potential to change oncology forever and this was the reason I did invest and have built up the largest holding by value I have ever put into a single AIM-listed company. I have to say though I do not expect it to stay in the long term an Aim Listed Company. My core holding here like many companies I have invested in will stay as long as the direction is maintained and I see continued growth and success.
I will continue to share my thoughts and summaries here and I hope the majority find that helpful.
I am sure very positive news is very close and the impact will be very strong growth.
Have a great day all!
My friend Ophidian posted a timeline of the processes here, based on years of experience in this industry. I am sure he will not mind me posting it for you!
"1. R&D work to establish a proof of concept - DONE
2. Development work to establish the design to take forward - DONE
3. Collaboration with third party device manufacturer to define product - DONE
4. Third party device manufacturer established final design to take forward - DONE
5. First batches to final design made at pilot scale (and put on stability to generate supporting data) - DONE
6. Examples from pilot scale devices supplied to Avacta for further evaluation and lab testing - DONE
(these are probably what he calls Prototypes)
7. Additional batches made again at pilot scale to clinical standards for first time clinical evaluation. Supplied Wk3/Wk4 June Time to complete 21-28 Days
8. In parallel with clinical programme; Scale up to production scale. Include Tech transfer and validation batches (again put on stability to generate data)
9. Evaluate data from clinical programme (establishes the Selectivity and Sensitivity of the test) July Wk.2s/wk3
10. Generate the Regulatory dossier including clinical data, stability data, development data and supporting data from early designs Wk2/wk3/wk4 July
11. Submit Regulatory dossier and if not already ongoing be manufacturing launch stocks 1st August
12. Get approval Wk3 August
13. Start selling Wk3/4 August
I am very happy with today's RNS (24th June) first lab batches tested and the LFD design now completely de-risked. There will be some minor tweaking now from the lab data to produce the batches that will be used for clinical validation and whilst they SHOULD freeze the process in this time of rapid development they won't and there will be further optimisations in the Xfer to production and tech transfers to manufacturing partners. This will be covered by ongoing commitments post-registration so won't hold anything up. Avacta have played an absolute blinder here I can't start to say how impressive their progress is to date. Now totally de-risked both LFD and BAMS will pretty soon dominate the market place in my view. Next RNS I want is manufacturing partners (and volumes potentially). I'm also interested in hearing what the selling price might be so we can start to rattle the piggy bank.
I made a minor amendment to the Timeline to mark lab tests as DONE - nothing else needs changing. All on course.
I hope this helps,
Yes, I am pointing people to another great write up on the Avacta News stream.
They would not be making so much of this if we were not about to release to the market on of the best ‘Point of Care’ diagnostic tools for testing yet seen. https://avacta.com/responding-to-disease-outbreaks-the-importance-of-point-of-care-diagnostics/
A worthy read.
Without furlough, many businesses would have gone and we would have a huge economic situation on our hands!
Business for many companies is very tough indeed right now. Even if they want to speed up due to demand, because of social distancing it is very difficult and will remain this way. The recovery from Covid will take years and we will need to adapt and new industries will come about.
The very difficult question is how much collateral damage will the world's governments be willing to accept and who will be protected and who will be coerced into working. The next 6 to 10 months is going to be critical. That gets us to April 2021. Workplace testing, not just temperature checks and questionnaires will have to mandatory every day to protect everyone coming into the workplace.
Shopping deliveries will become the only safe way to shop and people will have to plan better than they do today.
Let's hope that people come to their senses about mass gatherings and trips to the beach etc.
I absolutely think that Avacta's three opportunities to control and defeat covid19 will have a huge impact as the year progresses. I just hope we have the Virus blocker in place within 6 months and a strong partner will come forward for this project.
Good evening all,
I think from what I have been asking there are a huge number of mass spectrometers around the UK NHS and around the world, they are one of the key pieces of equipment in labs in hospitals. The key for Avacta is having the correct partners which are able to supply the trialled Affimers and distribute them for their machines. They certainly have the ability in the lab to actually become a very accurate test indeed and without the variances which have been found in PCR depending on the quality of the swabs. The attaraction to the specific protein from the Affimer being like iron fillings to a magnet means the results are going to be highly specific.
We are still looking forward to an update on these partnerships and we should be there very quickly.
The two tests are going to cover a huge global need for testing and the key will be consistency, simplicity and possibly the most important a cost advantage to health service business around the planet.
Given the current pathway by many governments including our own and peoples lack of a sensible response the requirements for testing are just going to multiply over and over both in lab and at point of care.
It will be such good news in every way for the populous and Avacta investors as soon as theses tests can become globally available.
The news items due in the immediate future are partnerships.
- production partnerships for LFD
- distribution partnerships for BAMS
- Pharmeceutical partnership for virus neutraliser
There after the detailed information on the testing options with the final production items.
Then the orders....
The largest market is going to be the America’s, north and south, Asia and Europe. I wonder if the UK maybe Avacta’s smallest market? Certainly in the short term.
The news I am really looking forward to is the commencement of phase 1 trials of the pre|CISION AVA6000 chemotherapy Affimer technology therapeutic.
I am very happy to wait and digest the news as it comes.
Have a good day all!
Likely to cover a short!
The SP jumped to 154 this morning in the RNS spike. Then dropped to £1.30. In just 90 minutes. How is that possible given the news.
That is thanks to shorting the stock. Look at the posts this morning.
It is clear.
It amazes me that when you have a full explanation of who the business can be valued - many thanks to Myles for being able to share this fully via his own website - it is clear how this business value calculated by some become clear. This is not ramping it is working out business value. I have shared pointers to this myself many times. Which has pointed to numbers similar to those given by Myles? Clearly we make slightly different assumptions but the numbers give an idea to investor value being created.
Yet there are a multitude of posters on this board who patrol it from morning till night, trying to downplay the real value here.
I would say the value is clear to see. Just because this is an AIM-listed business it does not mean it cannot succeed. It will.
I do hope that the many genuine investors who read this board can see through the rubbish posted here. Though it is not easy for the none business minded which is a great shame.
For those willing to invest and build up a holding here the future looks very good indeed. I would recommend you read the company website and the comments by Myles and try to ignore the less helpful comments posted here from morning till night by a small group trying to play this business down. They will not affect it. The company is driven by its IP and the market.
Avacta is a Biotech company with two operating segments, the Therapeutics operations based at Avacta’s Cambridge site (pre|CISION™ ) and the Diagnostics operations ( Affimer® ) in Wetherby.
Avacta has two key areas - Affimer® technology a uniquely developed technology which is used as a diagnostic to find virus’s based on a human protein called Stefin A. The Affimer® platform is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families.
Affimer® technology projects with LG Chem just on licensing can be worth up to $310 million.
ADC project backed by Astra Zeneca for PBD Warheads - loaded affirmer drugs $500 million.
A joint venture in South Korea with Daewoong a leading Korean pharma company, to develop the next generation of cell and gene therapies, incorporating Affimer proteins to enhance the immune-modulatory effects. Avacta holds 45% of the business but the finance is provided by venture capitalists where the market potential is still too large to actually pinpoint as there are NDA's in place so the market information can't be shared. Huge potential!
The huge project with Affimer® technology with Moderna which again will give drug deliveries for mRNA delivery is still progressing. Huge potential!
Affimer® technology to detect Covid19 using Antigen tests the partners are Cytiva (LFD) and Adeptrix (BOMS) with distribution through 4 Mass Spectrometer suppliers (both close to production)
There are existing 5 other Affirmer evaluations progressing, 17 other projects already delivered for evaluation, and a further 7 development projects initiated!
Avacta’s pre|CISION™ technology can be utilised in a drug conjugate linker or to generate chemotherapy pro-drugs that are only activated in the tumour.
When added to a chemotoxin, the pre|CISION™ substrate prevents the chemotoxin from entering cells and therefore renders it inert until the substrate is cleaved in the tumour microenvironment. Using this pro-drug approach, the systemic exposure to the chemotoxin is dramatically reduced, and the safety and therapeutic window of these powerful anti-cancer treatments are improved.
pre|CISION™ partnerships which are looking to start with opportunities in AST, Breast and Ovarian cancer the EU/ US market potential is around $1.5 billion.
Research Opportunities for the reader:
Broker Note: https://mcusercontent.com/d9ebd7c1aa0f3dbc5fab42eca/files/28b0a706-057a-4dda-bc5f-e24c2afca3cd/AvactaGroupplc_24_6_20_FINAL_BG.01.pdf
The last Presentation:
https://youtu.be/DzoxXCB4or0 - from 1hr 33min 50 seconds
Latest from Avacta: https://avacta.com/how-diagnostic-test-performance-is-measured/
A good read from a well-known researcher is found here:
Investment decision for 2020? Surely it looks good!
Good morning all,
It is amazing the company delivers the next stage of its progress and we get a vist from a 'silent watcher' today. How convenient. Shame you did join us all in February when you could have got in for 20p.
The company has in the last 3 months made huge progress. It clearly has Affitmer technology which does work, that has been proven by progress at Adeptrix and now Cytiva and now the LFA is being optimised by Cytiva ready for production at the soon to be announced UK production partners. The first of potentially a number of partners around the world.
Make no mistake that this is going to production and the accuracy of the positive and negativity as outlined yesterday is going to be at such a level that this will be a global bestseller.
In 6 months this company will have been transformed from a research biotech partner and developer to a full diagnostic supply production business having been given a massive opportunity.
The potential is hundreds of millions of sales with a profit margin for all partners and a margin for Avacta in excess of 70p per unit.
So 'Truth and Trust' - I don't think you are fooling anyone here with 'Deceit and Lies'. I think most people can see you have an alternative agenda who are well researched.
I am very happy to listen to what we are being told by the experts thanks very much. This company is one a pathway that you will not be able to stop. people need to listen to the CEO and consider the work that his team have brought this company too. The IP of Avacta is hugely valuable and in 2020 its value is going to be worth very much more and investors will see the impact of this.
This surely is one of the most significant days in Avacta’s progress as a company. The news the test works as outlined it would. But working with Cytiva for bringing the product together.
Now the completion of the design and likely announcements of a minimum of two production partnerships in the UK and then very likely overseas partners too.
One huge step.
Good day going to be here!
I do wonder if the BAMS test using our precise Affimer technology will be more sensitive and have an ability to be more specific even with less precise swabs. Surely we only need a saliva swabs. If they can use this effectively it will be the gold standard lab test.
Accuracy and simplicity as well as lower costs will be critical going forward. On BAMS compared to PCR we will be the newcomer, a bit like Blueray replacing DVD. Higher definition and clarity. That is key to virus checking.
Just my thoughts.
A must watch for all Avacta investors.
Today I bought another £20k’s worth of shares. They dropped the price I bought more. Thanks MM’s.
The portfolio is growing nicely.
What you all really need to know is what is the tooling capacity on the sub-contract injection moulders making the actual platform?
This is the key, then the rest is down to the assembly machines which put the whole LFD together which is what you see in the Abingdon Health video.
It is down to the machine cavitation and the cycle time and how many tools are set up ready to produce these new LFD for Saliva. Typically these type of moulding will run on a 10 second cycle time with a 32 or 48 cavity tool.
One machine can produce 414720 LFD's per day based on 48 cavity tool, so if we need 25 million per day, they will need 60 moulding machines! That is some requirement but based on global supply chain from multiple suppliers this is possible. But if it is new tooling it would take some time. I have been digging around many contacts in the medical device manufacturing world, but good old NDA'a do work! But the tooling, if it does not need to be a clean room, could be made very quickly.
Digging continues...but getting close ;-)
Dumbles you make some very valid points. We are entering a very dangerous situation in my opinion. The governments of the world are taking actions based on the economic situation and are not thinking about the people at all. It was about the NHS before. Now the numbers have fallen it is leading to a false sense of security.
The sky’s are filling with aircraft and people are traveling, thinking about holidays etc. But let’s not forget we have no cure and no vaccine. Sure we know how to test for it but the current situation is too slow and unreliable.
Then we have countries where there leaders are so stupid they either don’t want to test or they don’t believe in the virus.
If global leaders are so dumb they are not prepared to protect the people and people are so no foolish that they think everything is ok we will have an even bigger death toll in the potential Second wave. As an island the UK could keep safer if we kept our boarders closed or we make it mandatory for everyone traveling to the Uk to be tested once the fast tests are introduced. But right now we are not there. In a few weeks we should be.
Let’s hope the world finally has real leadership.